HIV, Merck

US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...
Merck (MRK) announced topline results from two pivotal Phase 3 trials of the investigational, oral, two-drug, single-tablet regimen of ...
The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.
U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...
(RTTNews) - Merck & Co Inc. (MRK), Thursday reported topline results from two pivotal Phase 3 trials evaluating the company's drug candidate islatravir in combination with its approved HIV drug ...